Imatinib mesylate does not increase bone volume in vivo

Calcified Tissue International

Volumn 88, Issue 1, 2011, Pages 16-22

  O'Sullivan, Susannah ^a   Naot, Dorit ^a   Callon, Karen E ^a   Watson, Maureen ^a   Gamble, Greg D ^a   Ladefoged, Marianne ^b   Karsdal, Morten A ^b   Browett, Peter ^a   Cornish, Jillian ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Bone; Bone formation; Imatinib; Osteoblast; Osteoclast

Indexed keywords

IMATINIB; OSTEOCALCIN; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE GROWTH; BONE MASS; BONE METABOLISM; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; IN VIVO STUDY; LOW DRUG DOSE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; TRABECULAR BONE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; CELL DIFFERENTIATION; DRUG EVALUATION, PRECLINICAL; FEMALE; ORGAN SIZE; OSTEOBLASTS; OSTEOCALCIN; OSTEOCLASTS; PIPERAZINES; PYRIMIDINES; RATS; RATS, WISTAR;

EID: 78951481931     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9429-1     Document Type: Article

References (50)

1. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes JJ Cornelissen T Fischer A Hochhaus T Hughes K Lechner JL Nielsen P Rousselot J Reiffers G Saglio J Shepherd B Simonsson A Gratwohl JM Goldman H Kantarjian K Taylor G Verhoef AE Bolton R Capdeville BJ Druker 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004 10.1056/NEJMoa022457 12637609
2. A Hochhaus SG O'Brien F Guilhot BJ Druker S Branford L Foroni JM Goldman MC Muller JP Radich M Rudoltz M Mone I Gathmann TP Hughes RA Larson IRIS Investigators 2009 Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 1054 1061 1:CAS:528:DC%2BD1MXntFygt7w%3D 10.1038/leu.2009.38 19282833
3. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann MW Deininger RT Silver JM Goldman RM Stone F Cervantes A Hochhaus BL Powell JL Gabrilove P Rousselot J Reiffers JJ Cornelissen T Hughes H Agis T Fischer G Verhoef J Shepherd G Saglio A Gratwohl JL Nielsen JP Radich B Simonsson K Taylor M Baccarani C So L Letvak RA Larson IRIS Investigators 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364
4. J Verweij A van Oosterom JY Blay I Judson S Rodenhuis W van der Graaf J Radford A Le Cesne PC Hogendoorn ED di Paola M Brown OS Nielsen 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur J Cancer 39 2006 2011 1:CAS:528: DC%2BD3sXmvVKgtrc%3D 10.1016/S0959-8049(02)00836-5 12957454
5. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts MC Heinrich DA Tuveson S Singer M Janicek JA Fletcher SG Silverman SL Silberman R Capdeville B Kiese B Peng S Dimitrijevic BJ Druker C Corless CD Fletcher H Joensuu 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 1:CAS:528: DC%2BD38XmtV2nt7s%3D 10.1056/NEJMoa020461 12181401
6. CD Blanke GD Demetri M von Mehren MC Heinrich B Eisenberg JA Fletcher CL Corless CD Fletcher PJ Roberts D Heinz E Wehre Z Nikolova H Joensuu 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 620 625 1:CAS:528:DC%2BD1cXis1alsL0%3D 10.1200/JCO.2007.13.4403 18235121
7. BL Eisenberg J Harris CD Blanke GD Demetri MC Heinrich JC Watson JP Hoffman S Okuno JM Kane M von Mehren 2009 Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665 J Surg Oncol 99 42 47 1:CAS:528:DC%2BD1MXhvFCjur0%3D 10.1002/jso.21160 18942073
8. J Cools DJ DeAngelo J Gotlib EH Stover RD Legare J Cortes J Kutok J Clark I Galinsky JD Griffin NC Cross A Tefferi J Malone R Alam SL Schrier J Schmid M Rose P Vandenberghe G Verhoef M Boogaerts I Wlodarska H Kantarjian P Marynen SE Coutre R Stone DG Gilliland 2003 A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med 348 1201 1214 1:CAS:528: DC%2BD3sXisVCqtrY%3D 10.1056/NEJMoa025217 12660384
9. M Baccarani D Cilloni M Rondoni E Ottaviani F Messa S Merante M Tiribelli F Buccisano N Testoni E Gottardi A de Vivo E Giugliano I Iacobucci S Paolini S Soverini G Rosti F Rancati C Astolfi F Pane G Saglio G Martinelli 2007 The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study Haematologica 92 1173 1179 1:CAS:528:DC%2BD2sXhtFGqu7jO 10.3324/haematol.11420 17666373
10. P Ault J Cortes C Koller ES Kaled H Kantarjian 2002 Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate Leukemia Res 26 881 884 1:CAS:528:DC%2BD38XlsVOmsb8%3D 10.1016/S0145-2126(02) 00046-2
11. AD Klion J Robyn C Akin P Noel M Brown M Law DD Metcalfe C Dunbar TB Nutman 2004 Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome Blood 103 473 478 1:CAS:528:DC%2BD2cXmsFCjsg%3D%3D 10.1182/blood-2003-08-2798 14504092
12. A Pardanani A Tefferi 2004 Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders Leukemia Res 28 Suppl 1 S47 S52 1:CAS:528:DC%2BD2cXhsVOgurs%3D 10.1016/j.leukres.2003.10.006
13. JR Taylor N Brownlow J Domin NJ Dibb 2006 FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance Oncogene 25 147 151 1:CAS:528:DC%2BD28Xht1ejsA%3D%3D 16170366
14. AL Dewar AC Zannettino TP Hughes AB Lyons 2005 Inhibition of c-fms by imatinib: expanding the spectrum of treatment Cell Cycle 4 851 853 1:CAS:528:DC%2BD28XhslCrtb8%3D 15917650
15. AL Dewar AC Cambareri AC Zannettino BL Miller KV Doherty TP Hughes AB Lyons 2005 Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood 105 3127 3132 1:CAS:528:DC%2BD2MXjtlSmur0%3D 10.1182/blood-2004-10-3967 15637141
16. E Day B Waters K Spiegel T Alnadaf PW Manley E Buchdunger C Walker G Jarai 2008 Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib Eur J Pharmacol 599 44 53 1:CAS:528:DC%2BD1cXhtlaqurrP 10.1016/j.ejphar.2008.10.014 18938156
17. S Parkkila A Innocenti H Kallio M Hilvo A Scozzafava CT Supuran 2009 The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms Bioorg Med Chem Lett 19 4102 4106 1:CAS:528:DC%2BD1MXosVGmsbk%3D 10.1016/j.bmcl.2009.06.002 19527930
18. AS Tsao H Kantarjian J Cortes S O'Brien M Talpaz 2003 Imatinib mesylate causes hypopigmentation in the skin Cancer 98 2483 2487 10.1002/cncr.11812 14635084
19. C Gambacorti-Passerini L Tornaghi F Cavagnini P Rossi F Pecori-Giraldi L Mariani N Cambiaghi E Pogliani G Corneo L Gnessi 2003 Gynaecomastia in men with chronic myeloid leukaemia after imatinib Lancet 361 1954 1956 10.1016/S0140-6736(03)13554-4 12801741
20. R Kerkela L Grazette R Yacobi C Iliescu R Patten C Beahm B Walters S Shevtsov S Pesant FJ Clubb A Rosenzweig RN Salomon RA Van Etten J Alroy JB Durand T Force 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 908 916 10.1038/nm1446 16862153
21. M Breccia M Muscaritoli G Alimena 2005 Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib Haematologica 90 Suppl ECR21 16266912
22. M Breccia M Muscaritoli Z Aversa F Mandelli G Alimena 2004 Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment J Clin Oncol 22 4653 4655 1:STN:280:DC%2BD2crmvFyrsA%3D%3D 10.1200/JCO.2004.04.217 15542819
23. D Veneri M Franchini E Bonora 2005 Imatinib and regression of type 2 diabetes N Engl J Med 352 1049 1050 1:CAS:528:DC%2BD2MXit1WrtL4%3D 10.1056/NEJM200503103521023 15758023
24. R Hagerkvist L Jansson N Welsh 2008 Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet Clin Sci 114 65 71 10.1042/CS20070122 17868036
25. R Hagerkvist S Sandler D Mokhtari N Welsh 2007 Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning FASEB J 21 618 628 10.1096/fj.06-6910com 17135364
26. R Hagerkvist N Makeeva S Elliman N Welsh 2006 Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro Cell Biol Int 30 1013 1017 10.1016/j.cellbi.2006.08.006 17020808
27. A Grey S O'Sullivan IR Reid P Browett 2006 Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism N Engl J Med 355 2494 2495 1:CAS:528:DC%2BD28Xht12ntb%2FF 10.1056/NEJMc062388 17151376
28. K Vandyke S Fitter AL Dewar TP Hughes AC Zannettino 2010 Dysregulation of bone remodeling by imatinib mesylate Blood 115 766 774 1:CAS:528: DC%2BC3cXhs1Giur8%3D 10.1182/blood-2009-08-237404 19890095
29. S O'Sullivan A Horne D Wattie F Porteous K Callon G Gamble P Ebeling P Browett A Grey 2009 Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib J Clin Endocrinol Metab 94 1131 1136 10.1210/jc.2008-2324 19174494
30. E Berman M Nicolaides RG Maki M Fleisher S Chanel K Scheu BA Wilson G Heller NP Sauter 2006 Altered bone and mineral metabolism in patients receiving imatinib mesylate N Engl J Med 354 2006 2013 1:CAS:528:DC%2BD28XksFGhs7s%3D 10.1056/NEJMoa051140 16687713
31. S Fitter AL Dewar P Kostakis LB To TP Hughes MM Roberts K Lynch B Vernon-Roberts AC Zannettino 2008 Long-term imatinib therapy promotes bone formation in CML patients Blood 111 2538 2547 1:CAS:528:DC%2BD1cXivFakt74%3D 10.1182/blood-2007-07-104281 18042796
32. S Osorio AG Noblejas A Duran JL Steegmann 2007 Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response Am J Hematol 82 394 395 1:CAS:528:DC%2BD2sXlsVKqsbg%3D 10.1002/ajh.20778 17117416
33. D Tibullo C Giallongo P La Cava S Berretta F Stagno A Chiarenza C Conticello GA Palumbo F Di Raimondo 2009 Effects of imatinib mesylate in osteoblastogenesis Exp Hematol 37 461 468 1:CAS:528:DC%2BD1MXjsVOhsbY%3D 10.1016/j.exphem.2008.12.008 19302920
34. F Fierro T Illmer D Jing E Schleyer G Ehninger S Boxberger M Bornhauser 2007 Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro Cell Prolif 40 355 366 1:CAS:528: DC%2BD2sXnt1GrtL8%3D 10.1111/j.1365-2184.2007.00438.x 17531080
35. S O'Sullivan D Naot K Callon F Porteous A Horne D Wattie M Watson J Cornish P Browett A Grey 2007 Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms J Bone Miner Res 22 1679 1689 10.1359/jbmr.070719 17663639
36. AL Dewar AN Farrugia MR Condina L Bik To TP Hughes B Vernon-Roberts AC Zannettino 2006 Imatinib as a potential antiresorptive therapy for bone disease Blood 107 4334 4337 1:CAS:528:DC%2BD28Xlt1CgsLo%3D 10.1182/blood-2005-09-3568 16449525
37. M Gallet R Mentaverri N Sevenet M Brazier S Kamel 2006 Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor Apoptosis 11 1909 1921 1:CAS:528:DC%2BD28XhtFKmtr3P 10.1007/s10495-006-9507-z 16927019
38. I El Hajj Dib M Gallet R Mentaverri N Sevenet M Brazier S Kamel 2006 Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity Eur J Pharmacol 551 27 33 1:CAS:528:DC%2BD28XhtFKmtbbO 10.1016/j.ejphar.2006.09.007 17049513
39. S Jonsson B Olsson C Ohlsson M Lorentzon D Mellstrom H Wadenvik 2008 Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia Haematologica 93 1101 1103 10.3324/haematol.12373 18508797
40. M Myllarniemi J Frosen LG Calderon Ramirez E Buchdunger K Lemstrom P Hayry 1999 Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo Cardiovasc Drugs Ther 13 159 168 1:CAS:528:DyaK1MXktFemtrc%3D 10.1023/A:1007700629728 10372232
41. W Ando J Hashimoto A Nampei H Tsuboi K Tateishi T Ono N Nakamura T Ochi H Yoshikawa 2006 Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA) J Bone Miner Metab 24 274 282 1:CAS:528:DC%2BD28XmsVShtr4%3D 10.1007/s00774-006-0684-1 16816921
42. LA Feldkamp 1984 Practical cone-beam algorithm J Opt Soc Am A Opt Image Sci Vis 1 612 619 10.1364/JOSAA.1.000612
43. JH Waarsing JS Day H Weinans 2004 An improved segmentation method for in vivo microCT imaging J Bone Miner Res 19 1640 1650 10.1359/JBMR.040705 15355559
44. T Hildebrand P Ruegsegger 1997 Quantification of bone microarchitecture with the structure model index Comput Methods Biomech Biomed Engin 1 15 23 10.1080/01495739708936692 11264794
45. M Hahn M Vogel M Pompesius-Kempa G Delling 1992 Trabecular bone pattern factor-a new parameter for simple quantification of bone microarchitecture Bone 13 327 330 1:STN:280:DyaK3s%2FgtFKmtg%3D%3D 10.1016/8756-3282(92)90078-B 1389573
46. AM Parfitt MK Drezner FH Glorieux JA Kanis H Malluche PJ Meunier SM Ott RR Recker 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 595 610 1:STN:280:DyaL1czjvVemsQ%3D%3D 10.1002/jbmr.5650020617 3455637
47. IR Reid 2008 Relationships between fat and bone Osteoporos Int 19 595 606 1:STN:280:DC%2BD1c3hslGlug%3D%3D 10.1007/s00198-007-0492-z 17965817
48. Y Jiang JJ Zhao BH Mitlak O Wang HK Genant EF Eriksen 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure J Bone Miner Res 18 1932 1941 1:CAS:528: DC%2BD3sXptVyiu74%3D 10.1359/jbmr.2003.18.11.1932 14606504
49. RR Recker PD Delmas J Halse IR Reid S Boonen PA Garcia-Hernandez J Supronik EM Lewiecki L Ochoa P Miller H Hu P Mesenbrink F Hartl J Gasser EF Eriksen 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J Bone Miner Res 23 6 16 1:CAS:528: DC%2BD1cXhtVCmt7c%3D 10.1359/jbmr.070906 17892374
50. Hatfield A, Owen S, Pilot PR (2007) In reply to "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate". Nat Med 13:13, author reply 15-16